Clinical applications include localized prostate cancer (combined with possibly external beam radiotherapy or brachytherapy) as well as for advanced disease including CRPC, oligoprogressive CRPC, and oligometastatic prostate cancer by combining ralaniten analogs with stereotactic radiation therapy, radium-223, or targeted alpha emitters such as 225Ac-labeled PSMA-617. The gene discussed is FOLH1; the disease is prostate carcinoma.